What is idiopathic pulmonary fibrosis?

Written in association with: Dr Tim Gatheral
Published:
Edited by: Conor Lynch

In this article below, established and well-respected consultant respiratory physician, Dr Tim Gatheral, provides us with an all-we-need-to-know guide with regards to idiopathic pulmonary fibrosis.

What is idiopathic pulmonary fibrosis?

Idiopathic pulmonary fibrosis (IPF) is a chronic and progressive lung disease characterised by the scarring and thickening of the lung tissue, which leads to a decline in lung function over time.

 

What causes the condition?

IPF primarily affects older adults, typically those over the age of 50, although it can occur at any age. The exact cause of IPF is not well understood, but it is believed to involve a combination of genetic predisposition, environmental factors, and abnormal wound healing processes in the lungs.

 

Smoking, exposure to certain environmental pollutants or occupational hazards, viral infections, and gastroesophageal reflux disease (GERD) have been suggested as potential risk factors for developing IPF, although not all individuals with these risk factors will develop the disease.

 

What are the main associated symptoms?

The hallmark symptom of IPF is progressive dyspnoea (shortness of breath), which worsens over time and is often accompanied by a persistent dry cough. Other common symptoms may include fatigue, weight loss, chest discomfort or tightness, and clubbing of the fingers or toes (enlargement and rounding of the fingertips or toes). IPF can significantly impact quality of life and daily activities, leading to functional limitations and reduced exercise tolerance.

 

How is idiopathic pulmonary fibrosis diagnosed?

Diagnosing IPF can be challenging, as the symptoms are non-specific and can mimic those of other lung diseases. A thorough medical history, physical examination, and diagnostic tests such as pulmonary function tests, high-resolution computed tomography (HRCT) scans, and rarely lung biopsies may be necessary to confirm the diagnosis and rule out other potential causes of pulmonary fibrosis.

 

What are the treatment options?

Treatment for IPF aims to slow disease progression, relieve symptoms, and improve quality of life. While there is currently no cure for IPF, several medications, including pirfenidone and nintedanib, have been approved for the treatment of IPF and have been shown to slow the decline in lung function and reduce the risk of disease progression.

 

Oxygen therapy, pulmonary rehabilitation, and lung transplantation may also be considered for individuals with advanced IPF or severe symptoms.

 

In addition to medical treatment, lifestyle modifications such as smoking cessation, avoiding environmental pollutants or respiratory irritants, and staying physically active can help manage symptoms and improve overall health in individuals with IPF. Regular monitoring and follow-up care with a healthcare provider experienced in managing IPF are essential for optimising treatment outcomes and addressing any changes in symptoms or lung function over time.

 

To schedule in an appointment with Dr Tim Gatheral today, simply visit his Top Doctors profile. 

By Dr Tim Gatheral
Pulmonology & respiratory medicine

Dr Tim Gatheral is a leading consultant respiratory physician based in Preston, who specialises in chronic cough, breathlessness, bronchiectasis and chronic obstructive pulmonary disease (COPD), as well as interstitial lung disease (ILD) including pulmonary fibrosis. His NHS work is based at Lancashire Teaching Hospitals Trust and University Hospitals of Morecambe Bay NHS Foundation Trust (UHMB).  His private clinic is located at the Greater Lancashire Hospital in Preston. 

Dr Gatheral is highly qualified, with a MA (1999) and MB BChir (2002) from the University of Cambridge. After post-graduate training in London Dr Gatheral undertook a period of research at the National Heart and Lung Institute and Royal Brompton Hospital leading to the award of a PhD from Imperial College London in 2012.

He runs the specialist Interstitial Lung Disease clinic at his NHS hospital, specialising in Idiopathic Pulmonary Fibrosis (IPF), which is a form of ILD characterised by damage to the lung accompanied by an uncontrolled healing response that causes progressive scarring or thickening (fibrosis) of tissues between the lungs' air sacs. 

Dr Gatheral is a respected name in his field as a lead member of the Morecambe Bay Respiratory Network (an integrated respiratory care network promoting excellence in respiratory care diagnosis and management), and also in clinical academia. He is a senior clinical lecturer at Lancaster Medical School where he is co-director of Year 3, and his research has been published in various peer-reviewed journals. He is principle investigator for several university and industry led clinical research trials in Morecambe Bay.

Dr Gatheral has recently been appointed as the director of research and development at UHMB and has held previous managerial roles at the trust including  clinical lead for respiratory medicine.

View Profile

Overall assessment of their patients


  • Related procedures
  • Depression
    Sleep disorders
    Snoring
    Rhinitis
    Obstructive sleep apnea
    Restless legs syndrome
    Autoimmune diseases
    Atypical pneumonia
    Asthma
    Methacholine challenge test
    This website uses our own and third-party Cookies to compile information with the aim of improving our services, to show you advertising related to your preferences as well analysing your browsing habits. You can change your settings HERE.